Medicines on the horizon
Explains how new IBD medicines move from lab testing through clinical trials to licensing, and describes medicines currently in late-stage testing.
Jargon explained clinical trial licensing phase 3
Everything here about research studies, trials and reviews: our articles first, then short answers, the words you may hear, and the original sources.
The Crohn's Disease Activity Index (CDAI) is an older, longer score. It needs a 7-day symptom diary, your weight and a blood test result, so it takes more effort to work out. A CDAI under 150 is taken as a marker of remission and over 450 as a marker of severe Crohn's. The Harvey-Bradshaw Index is a simpler score based on just the previous day's symptoms and does not need a blood test.
Sources
It means your team agrees goals in advance and adjusts treatment until you reach them, rather than waiting for symptoms. The STRIDE-II expert agreement says early goals are feeling better and getting blood and poo inflammation tests back to normal; longer-term goals are a healed bowel lining, no disability, good quality of life and normal growth in children. The CALM trial found that stepping up treatment when tests showed inflammation, not just when symptoms flared, led to more bowel healing.
Sources
Ask your IBD team whether your hospital is running any studies. You can also search the NIHR's Be Part of Research website, which lists UK studies currently recruiting people with Crohn's. The IBD BioResource invites people with Crohn's or colitis to join a national panel and be contacted about future studies. Crohn's & Colitis UK also lists ways to help shape research, such as patient and public involvement.
Sources
Top-down means starting strong treatment, such as a biologic plus an immunosuppressant, soon after diagnosis instead of trying milder medicines first ('step-up'). In the UK PROFILE trial of newly diagnosed adults, 79% on top-down treatment stayed in remission without steroids or surgery for a year, compared with 15% on step-up, with fewer flares and operations. Your team will weigh this up for your own situation.
Source
There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.
Sources
We do not know yet. Cochrane found only two small trials of probiotics for active Crohn's and called the evidence very uncertain. For faecal microbiota transplant (putting donor poo into the bowel), Cochrane also found the evidence in Crohn's too uncertain to draw any conclusions. Both are areas of ongoing research.
Sources
Partly. In 2001 researchers found the first gene firmly linked to Crohn's, NOD2, which helps the immune system recognise bacteria. Later large studies found many more gene regions, each adding a small amount of risk, and many are shared with other immune conditions. Having these gene changes does not mean you will get Crohn's; gut bacteria and environment also play a part.
Sources
The IBD Standards, written by the IBD UK alliance, set out what good care looks like across the whole journey, from before diagnosis to flares, surgery, hospital stays and ongoing care. IBD UK's reports show many services fall short, for example with long waits for diagnosis and too few IBD nurses, dietitians and psychologists.
Sources
Cochrane reviews are systematic reviews: researchers find every good trial on a question, judge how reliable each one is and combine the results. They also grade how certain the evidence is. For Crohn's, Cochrane has found strong evidence for some treatments, such as vedolizumab, and too little evidence to judge others, such as treatments for fatigue.
Sources
The NHS suggests asking your doctor or a patient organisation about trials you may be eligible for. You can also search the NIHR's Be Part of Research website for UK studies and contact research teams directly. Registries such as ISRCTN and ClinicalTrials.gov list studies and their results. Crohn's & Colitis UK explains how new medicines are tested before they are licensed.
Sources
The original NHS, NICE, charity and research pages on this topic, with our summary of each.
Explains how new IBD medicines move from lab testing through clinical trials to licensing, and describes medicines currently in late-stage testing.
Jargon explained clinical trial licensing phase 3
The NHS explains what a clinical trial is and how to find one. It suggests asking your doctor or a patient organisation, and points to the Be Part of Research website, where you can search UK studies and contact researchers.
Topics Research
Jargon explained clinical trial randomised
Crohn's & Colitis UK's starting point for people who want to help with research. It explains patient and public involvement, where people with Crohn's help shape studies, and the charity's Research Champions, and lists current opportunities.
Topics Research
Jargon explained patient and public involvement
Explains how Crohn's & Colitis UK funds research, including its 2026-2030 research strategy, the projects it is funding and the difference past research has made. The charity says it has funded research since 1979.
Topics Research
Jargon explained research strategy grant
A national NIHR project that builds a large panel of people with Crohn's and colitis who agree to share samples and health data and to be invited into future studies. It aims to understand the genetic causes of IBD and why people respond differently to treatment. There is also a children's arm.
Topics Research
Jargon explained bioresource cohort genetic analysis
Reports a University of Nottingham study, funded by the charity and Coeliac UK, that looked at GP records for 38.3 million people. It found more than half a million people in the UK, about 1 in every 123, live with Crohn's, ulcerative colitis or unclassified IBD, almost twice the previous estimate of 300,000.
Topics About Crohn's disease Research
Jargon explained prevalence incidence
Covers treatments beyond the main drug groups: medicines for symptoms such as diarrhoea and pain, antibiotics for complications, nutritional treatments and supplements, and newer approaches only available through clinical trials.
Topics Medicines Diet and nutrition Research
Jargon explained antibiotics nutritional therapy faecal microbiota transplant
The NHS research service's search tool for finding health studies to take part in across the UK. Searching for Crohn's disease lists studies currently recruiting, with who can join and where. A good first stop if you want to volunteer for a trial.
Topics Research
Jargon explained clinical trial recruiting
A WHO-recognised registry where UK and international studies are recorded before they start, with their aims and progress. You can search it free for Crohn's studies, including UK trials such as PROFILE. Records are written for researchers, so they can be technical.
Topics Research
Jargon explained trial registry study protocol ISRCTN number
The largest worldwide database of clinical studies, run by the US government. It includes many trials running at UK hospitals, often drug-company trials of new Crohn's medicines. Each record lists the study's aim, who can join and where.
Topics Research
Jargon explained clinical trial eligibility criteria trial registry NCT number
The UK-wide standards for IBD care from the IBD UK alliance, updated in 2026 with 60 statements built on the experiences of about 26,000 patients. The pre-diagnosis section calls for local referral pathways using calprotectin and/or FIT, a specialist appointment or straight-to-test within four weeks of referral, and endoscopy and scans within 6 weeks for routine care and 2 weeks if urgent, favouring MRI and ultrasound because they avoid radiation. A patient version is available.
Topics Diagnosis and tests Monitoring Living well Research
Jargon explained faecal calprotectin faecal immunochemical test referral MRI enterography intestinal ultrasound IBD Standards multidisciplinary team
A national report on how well UK IBD services meet the 2019 IBD Standards, based on 2023 surveys of 150 hospital services and over 17,600 patients or parents. It makes recommendations for improving care and is aimed at hospital leaders and politicians.
Topics Research Living well
Jargon explained benchmarking IBD standards
IBD UK's 2021 report, drawing on more than 10,000 patients and most UK IBD services. It found people waited too long for diagnosis, pain, fatigue and emotional wellbeing were often ignored, specialist help was slow, there were too few IBD nurses, dietitians and psychologists, and care was often not joined up.
Topics Research Living well Diagnosis and tests
Jargon explained benchmarking IBD nurse specialist
Faecal microbiota transplant (FMT) means putting poo from a healthy donor into the bowel to change the gut bacteria. For Crohn's, the evidence is very uncertain and no conclusions could be drawn about whether it works. More trials are needed.
Jargon explained faecal microbiota transplant microbiome
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics Biologics and newer medicines Research
Jargon explained network meta-analysis relative risk number needed to treat biosimilar
A plain-language summary of a Cochrane review. It concludes that psychological treatments probably give a small improvement in quality of life, depression and anxiety in adults with IBD, and probably improve quality of life in teenagers. Any effect on inflammation or physical symptoms is very uncertain.
Topics Mental health Research
Jargon explained psychological interventions systematic review
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics Biologics and newer medicines Research
Jargon explained combination therapy purine analogue biosimilar CT-P13
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics Biologics and newer medicines Research
Jargon explained high-certainty evidence induction maintenance integrin
Tummy pain often continues in Crohn's even when inflammation is under control. This review looked for treatments aimed at the pain itself but found so few, small studies that no conclusions could be drawn.
Jargon explained abdominal pain sham remission stricture adhesions low fodmap diet
Looks at iron tablets and iron drips for anaemia caused by low iron in IBD. The reviewers found the evidence too weak to say for certain which works best, even though both are widely used and guidelines favour drips. They highlight this as an important gap.
Jargon explained iron deficiency anaemia intravenous iron ferric carboxymaltose
A Cochrane review of 14 studies, covering both drug and non-drug treatments such as exercise and psychological approaches, for fatigue in IBD. The reviewers concluded the evidence is too uncertain to say which treatments work and called for trials designed specifically around fatigue.
Jargon explained fatigue systematic review
Fatigue is one of the most common complaints in IBD, but this review found too little good-quality research to say which treatments help. The authors call for bigger studies that measure fatigue as the main outcome.
Jargon explained fatigue low certainty evidence systematic review cognitive behavioural therapy
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
A Cochrane review of 18 trials that tested cutting down or cutting out foods thought to provoke IBD symptoms. The authors found the evidence too weak to say whether any of these diets help bring on or keep remission, and called for better trials. This summary dates from 2019.
Topics Diet and nutrition Research
Jargon explained remission exclusion diet randomised controlled trial
Antibiotics may give a small benefit for active Crohn's, but probably not enough to make a real difference for most people. They did not cause more side effects than placebo. Whether they help keep Crohn's in remission is unclear. Note this is about treating the Crohn's itself, not infections or abscesses.
Jargon explained antibiotic clinically meaningful antibiotics induction maintenance
Cochrane pooled the trials of azathioprine and mercaptopurine for keeping Crohn's quiet. Low-quality evidence suggests azathioprine works better than placebo, but side effects such as pancreatitis, low white cell counts, sickness and infections limit its use. More good-quality trials are needed.
Topics Immunosuppressants Research
Jargon explained thiopurine low-quality evidence adverse event remission placebo systematic review
Budesonide, a steroid that acts mainly in the gut, works better than placebo for bringing on remission. It is a bit less effective than standard steroids such as prednisolone, especially for severe or widespread colon disease, but causes fewer side effects and less suppression of the body's own steroid production.
Jargon explained budesonide corticosteroid adrenal suppression conventional steroids
A Cochrane review concluding that budesonide does not keep Crohn's in remission, especially beyond three months. Small benefits were outweighed by more side effects and adrenal suppression.
Jargon explained budesonide maintenance adrenal suppression
A Cochrane review finding moderate-quality evidence that methotrexate given by injection helps keep Crohn's in remission and appears safe, while low-dose tablets did not appear effective in the trials reviewed. Adding methotrexate to infliximab did not improve remission rates.
Topics Immunosuppressants Research
Jargon explained methotrexate intramuscular maintenance
A Cochrane review confirming standard steroids are effective for bringing active Crohn's into remission. They cause more side effects than placebo, and more research was needed on the best length of treatment and how to reduce them.
Jargon explained corticosteroids induction tapering
A Cochrane review suggesting that stepping up treatment based on a colonoscopy after surgery may reduce Crohn's coming back compared with waiting for symptoms. Whether to start treatment immediately after surgery or only after a colonoscopy remains uncertain.
Topics Surgery Monitoring Research
Jargon explained post-operative recurrence colonoscopy prophylaxis
Looks at whether azathioprine or mercaptopurine help stop Crohn's coming back after an operation. The evidence is weak: they may be a little better than placebo, may cause more side effects than mesalazine-type drugs, and may be less effective than anti-TNF biologics, but no firm conclusions can be drawn.
Topics Immunosuppressants Surgery Research
Jargon explained postoperative recurrence low certainty evidence post-operative recurrence thiopurine 5-ASA anti-TNF
Compares liquid-only feeding (EN) with steroids for settling a Crohn's flare. Very low-quality evidence suggests steroids may work better in adults, while liquid feeds may work better in children. The type of formula did not seem to matter. The reviewers suggest EN for children, and for adults who can manage it or need to avoid steroids.
Topics Diet and nutrition Steroids Children and young people Research
Jargon explained enteral nutrition polymeric formula elemental diet nasogastric tube elemental feed polymeric feed
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics Biologics and newer medicines Research
Jargon explained non-inferiority endoscopic remission anti-TNF
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics Biologics and newer medicines Research About Crohn's disease
Jargon explained top-down treatment step-up treatment biomarker steroid-free remission top-down step-up immunomodulator randomised controlled trial
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics Biologics and newer medicines Research
Jargon explained head-to-head trial biologic-naive confidence interval
This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.
Topics Biologics and newer medicines Research
Jargon explained maintenance therapy remission placebo
Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.
Topics Medicines Immunosuppressants Research
Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics Monitoring Biologics and newer medicines Research
Jargon explained tight control faecal calprotectin CRP mucosal healing treat to target
A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.
Topics Surgery Biologics and newer medicines Research
Jargon explained laparoscopic ileocaecal resection terminal ileum quality of life terminal ileitis
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics Biologics and newer medicines Immunosuppressants Research
Jargon explained combination therapy steroid-free remission mucosal healing randomised controlled trial
The UK registry that collects health data from people with IBD to help improve care and support research. It has been running since 2012 and joined NHS England in 2026. Hospital teams use it to compare their services, and people with IBD can find out what data is collected about them.
Topics Research Monitoring
Jargon explained registry quality improvement
Using UK GP records from 2000 to 2017, this study found Crohn's became more common, rising from about 220 to 400 per 100,000 people. It predicted about 1 in 90 people in the UK would have IBD by 2025. Colitis was linked to a higher risk of bowel cancer, and both conditions to a somewhat higher risk of death than people without IBD.
Topics About Crohn's disease Cancer risk and screening Research
Jargon explained epidemiology prevalence hazard ratio all-cause mortality
The 2025 update of the UK specialist guideline for adults with Crohn's or colitis, replacing the 2019 version. It is designed to sit alongside the IBD UK Standards and to encourage GPs to use the national referral pathway for bowel symptoms, so people get diagnosed sooner and more accurately. It was written without drug-company funding and is aimed mainly at the UK, though it can be used elsewhere.
Topics Research Medicines Diagnosis and tests Monitoring
Jargon explained guideline primary care diagnostic pathway
An international expert agreement on what 'treat to target' should aim for in IBD. Short-term goals are feeling better and getting blood and poo inflammation tests back to normal. Long-term goals include a healed bowel lining seen at endoscopy, no disability, a normal quality of life, and normal growth in children. Healing through the full bowel wall in Crohn's is not yet a formal target but is a sign of deeper remission.
Topics Monitoring Research Medicines
Jargon explained treat to target endoscopic healing transmural healing biomarker calprotectin CRP clinical remission
The American College of Gastroenterology's 2025 update on diagnosing and treating Crohn's in adults, replacing its 2018 guideline. It reflects how much treatment has changed in recent years. Like other US guidance, it is a useful comparison to UK practice rather than a guide to what the NHS offers.
Topics Medicines Diagnosis and tests Research
Jargon explained idiopathic etiology
The free full text of the 2019 BSG guideline, written with surgeons, specialist nurses, dietitians, radiologists, GPs and Crohn's & Colitis UK. It reviewed a very large body of research to make recommendations for adults with IBD. It has been replaced by the 2025 guideline but is a freely readable reference on diagnosis and assessment.
Topics About Crohn's disease Diagnosis and tests Monitoring Research Medicines Surgery
Jargon explained inflammatory bowel disease consensus guideline IBD
The evidence documents NICE used to write its Crohn's guideline for England and Wales. They set out which studies NICE looked at and how it weighed them up before making each recommendation. Most date from the 2012 guideline, with a 2019 update. Worth reading if you want to know why NICE recommends what it does.
Topics Research Medicines Surgery
Jargon explained evidence review cost-effectiveness
A 2025 open-access analysis comparing types of psychological therapy for people with IBD. Mindfulness and CBT reduced depression, acceptance and commitment therapy and CBT reduced anxiety, and CBT ranked well for stress. The authors see these therapies as useful additions to medical care, with uncertain effects on disease activity.
Topics Mental health Research
Jargon explained cognitive behavioural therapy mindfulness acceptance and commitment therapy network meta-analysis
An open-access review of studies on helping people with Crohn's stop smoking. Its background summarises evidence that smokers with Crohn's have more flares and operations and that people who quit can do as well as non-smokers. It concludes that stop-smoking support tailored to people with Crohn's needs more study.
Topics Living well Research
Jargon explained smoking cessation systematic review
Reviews the evidence for 'treat to target', where treatment is adjusted not just to symptoms but to measured goals such as a healed bowel lining and normal blood or poo markers. It explains the idea behind the STRIDE targets and notes that firm proof that aiming for healing improves long-term outcomes was still emerging.
Topics Monitoring Research
Jargon explained treat to target mucosal healing biomarker STRIDE
A UK review pooling studies of how accurate the calprotectin poo test is at detecting IBD in adults with long-standing gut symptoms. Only a handful of the eligible studies were done in general practice, and the results varied too much between studies to compare GP and hospital settings properly. It is useful background on why calprotectin helps but is not a perfect test.
Topics Diagnosis and tests Research
Jargon explained faecal calprotectin sensitivity specificity meta-analysis
A review of population studies from around the world. In Western countries the number of new cases is levelling off but more than 0.3% of people now live with IBD. In newly industrialised countries in Asia, Africa and South America, new cases are rising quickly as lifestyles become more Western.
Topics About Crohn's disease Research
Jargon explained systematic review incidence prevalence population-based study
A Cochrane review of 75 trials of medical treatments for anal fissure, such as GTN ointment, calcium channel blocker creams and botox. Medicines helped some fissures heal but less reliably than surgery, and fissures often came back. Fissures linked to IBD were excluded, so results may not fully apply to Crohn's.
Topics Around the bottom (perianal) Research
Jargon explained anal fissure glyceryl trinitrate sphincterotomy
Five-year follow-up of the PROFILE trial. People who had early top-down treatment were less likely to be admitted to hospital or to develop strictures or fistulas than those treated step-up, with no difference seen in serious infections or cancers, suggesting early treatment may change the course of the disease.
Topics Biologics and newer medicines Research
Jargon explained top-down step-up disease modification stricturing penetrating disease
A review describing bowel urgency as a distressing, often overlooked symptom that is about more than inflammation alone and strongly affects daily life. It calls for better, standard ways to measure urgency in clinics and trials.
Topics Toilet habits Research
Jargon explained bowel urgency
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
Topics Biologics and newer medicines Research
Jargon explained IL-23 maintenance placebo endoscopic response
A study of more than 11 million people's GP records from 2000 to 2018 tracking new IBD diagnoses in the UK. It found new cases in adults were stable or falling, but UK rates are among the highest reported anywhere, with a large rise in new diagnoses among teenagers.
Topics About Crohn's disease Research
Jargon explained incidence prevalence cohort study primary care
Part of the Global Burden of Disease project, estimating about 6.8 million people with IBD worldwide in 2017. Rates were highest in wealthier countries, and the UK had the second highest age-adjusted rate after the USA.
Topics About Crohn's disease Research
Jargon explained prevalence inflammatory bowel disease disability-adjusted life years age-standardised rate
A large study of the gut bacteria of children newly diagnosed with Crohn's, before any treatment. It found a clear pattern: more of certain potentially harmful bacteria and fewer of some helpful groups. Antibiotics made the imbalance worse. Samples from the rectum lining looked promising as a possible early diagnostic test.
Topics About Crohn's disease Research Children and young people
Jargon explained microbiome dysbiosis treatment-naive
A huge international genetics study that mapped many gene regions linked to Crohn's and colitis. Many of these are shared with other immune conditions such as ankylosing spondylitis and psoriasis, and with the body's response to bacteria such as those that cause TB. It shows IBD risk is spread across many genes, each adding a small amount.
Topics About Crohn's disease Research
Jargon explained genome-wide association study locus immune-mediated disease
One of two papers published together in 2001 that found the first gene firmly linked to Crohn's, NOD2. A change in this gene produces a faulty version of a protein that normally helps the immune system recognise bacteria. It pointed to an abnormal reaction to gut bacteria as part of what causes Crohn's.
Topics About Crohn's disease Research
Jargon explained NOD2 mutation susceptibility gene innate immunity
The companion to the other 2001 NOD2 paper. It found several variants of the NOD2 gene linked to Crohn's, all in the part of the protein that senses bits of bacteria. It suggested that people with these variants may handle gut bacteria differently, a key step in understanding the causes of Crohn's.
Topics About Crohn's disease Research
Jargon explained NOD2 gene variant genetic susceptibility
A look back at 157 adults with Crohn's and a single abscess inside the tummy, treated at 14 specialist centres in nine countries. People whose abscess was first drained through the skin with a scan-guided tube had fewer hospital admissions and fewer complications afterwards than those who went straight to planned surgery, though most still had an operation later. The authors say drainage first can be the preferred start, but the study was not randomised.
Topics Complications Surgery Research
Jargon explained intra-abdominal abscess percutaneous drainage resection penetrating Crohn's
A UK trial at eight NHS hospitals comparing MRI enterography with bowel ultrasound in 284 people with new or relapsing Crohn's. Both were very good at spotting small bowel Crohn's and were judged valid first tests and alternatives to colonoscopy of the ileum, but MRI was more accurate at mapping how much bowel was affected. The authors concluded MRI is generally preferred in the NHS where available.
Topics Diagnosis and tests Monitoring Research
Jargon explained MRI enterography intestinal ultrasound small bowel sensitivity
A Spanish multi-centre study of 94 people with Crohn's and low B12, many after ileal surgery. Most who took B12 by mouth reached normal levels, suggesting tablets may be an option for some instead of injections. Treatment choices should be made with your own team.
Topics Anaemia Diet and nutrition Research
Jargon explained vitamin b12 deficiency cyanocobalamin ileal resection
A trial of how to stop Crohn's returning after bowel surgery. Treating people according to their risk, checking with a colonoscopy at six months and stepping up treatment if the disease had come back worked better than standard drug treatment alone. It also showed that even low-risk patients need monitoring.
Topics Surgery Monitoring Research
Jargon explained post-operative recurrence colonoscopy step-up resection
Explains that no single cause of Crohn's has been proven and that it is thought to be an immune-driven condition set off by environmental triggers in people whose genes make them susceptible. It covers family history, smoking (which raises the risk of Crohn's, unlike UC, and is linked to flare-ups and surgery), a past bout of infectious gastroenteritis and other factors that have been studied.
Topics About Crohn's disease Research
Jargon explained immune-mediated gastroenteritis appendicectomy
NICE's GP summary on how common Crohn's is. It says exact figures are not known because studies count cases differently, that new cases are thought to be stable or falling in Europe and the US but rising in newly industrialised countries, and that Crohn's usually starts in the teenage and young adult years, with a median age at diagnosis of about 30. Men and women are affected about equally.
Topics About Crohn's disease Research
Jargon explained incidence prevalence
Another big UK GP-records study, covering 2006 to 2016. It found IBD rose by about a third over that time to roughly 1.4% of patients, higher than earlier estimates. The authors point out that the answer depends heavily on how a 'case' is defined, which may explain why older figures were lower.
Topics About Crohn's disease Research
Jargon explained retrospective cohort study prevalence incidence
An online CDAI calculator. It shows that the CDAI needs a 7-day symptom diary, body weight and a blood test result, and explains that a score under 150 is a marker of remission and over 450 a marker of severe Crohn's.
Topics Monitoring Research
Jargon explained Crohn's Disease Activity Index haematocrit remission